Literature DB >> 17429640

Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media.

Carlo Bartolozzi1, Laura Crocetti, Riccardo Lencioni, Dania Cioni, Clotilde Della Pina, Daniela Campani.   

Abstract

The development and progression of a hepatocellular carcinoma (HCC) in a chronically diseased liver, i.e., the carcinogenesis, comprise a multistep and long-term process. Morphologically, this process is associated with the presence of distinct nodular lesions in the liver that are called 'preneoplastic lesions.' These preneoplastic lesions are associated with and can precede the growth and progression of well-differentiated HCCs . The characterization of nodular lesions and demonstration of the multistep development of HCC in the cirrhotic liver by imaging modalities represent a challenging issue. The arterial hypervascular supply, depicted by different dynamic studies, represents a fundamental radiological criterion for the diagnosis of HCC in cirrhosis. Magnetic resonance (MR) imaging performed with tissue-specific contrast media can help to investigate the "grey area" of carcinogenesis, in which significant histological changes are already present without any imaging evidence of neoangiogenesis. The purpose of this review is to provide information on the properties of tissue-specific MR contrast agents and on their usefulness in the demonstration of the pathologic changes that take place at the level of the biliary and reticuloendothelial systems during the carcinogenetic process in liver cirrhosis.

Entities:  

Mesh:

Year:  2007        PMID: 17429640     DOI: 10.1007/s00330-007-0602-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  73 in total

Review 1.  Contrast agents for MR imaging of the liver.

Authors:  R C Semelka; T K Helmberger
Journal:  Radiology       Date:  2001-01       Impact factor: 11.105

2.  Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number.

Authors:  J H Lim; D Choi; S K Cho; S H Kim; W J Lee; H K Lim; C K Park; S W Paik; Y I Kim
Journal:  Radiology       Date:  2001-09       Impact factor: 11.105

3.  Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study.

Authors:  S Terasaki; S Kaneko; K Kobayashi; A Nonomura; Y Nakanuma
Journal:  Gastroenterology       Date:  1998-11       Impact factor: 22.682

4.  Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging.

Authors:  O Clement; G Frija; C Chambon; E Schouman-Clayes; J F Mosnier; M F Poupon; B Balkau
Journal:  Radiology       Date:  1991-07       Impact factor: 11.105

5.  Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.

Authors:  Martina Scharitzer; Wolfgang Schima; Ewald Schober; Peter Reimer; Thomas K Helmberger; Nicolaus Holzknecht; Alfred Stadler; Ahmed Ba-Ssalamah; Michael Weber; Friedrich Wrba
Journal:  J Comput Assist Tomogr       Date:  2005 Mar-Apr       Impact factor: 1.826

6.  Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading.

Authors:  Y Imai; T Murakami; S Yoshida; M Nishikawa; M Ohsawa; K Tokunaga; M Murata; K Shibata; S Zushi; M Kurokawa; T Yonezawa; S Kawata; M Takamura; H Nagano; M Sakon; M Monden; K Wakasa; H Nakamura
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

7.  MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.

Authors:  Ji Hyun Youk; Jeong Min Lee; Chong Soo Kim
Journal:  AJR Am J Roentgenol       Date:  2004-10       Impact factor: 3.959

8.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.

Authors:  B Hamm; T Staks; A Mühler; M Bollow; M Taupitz; T Frenzel; K J Wolf; H J Weinmann; L Lange
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

9.  The uptake of manganese dipyridoxal-diphosphate by chemically induced hepatocellular carcinoma in rats. A correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation, and vascularization.

Authors:  Y Ni; G Marchal; X Zhang; P Van Hecke; J Michiels; J Yu; E Rummeny; K P Lodemann; A L Baert
Journal:  Invest Radiol       Date:  1993-06       Impact factor: 6.016

10.  Mn-DPDP enhancement patterns of hepatocellular lesions on MR images.

Authors:  T J Vogl; B Hamm; B Schnell; C McMahon; G Branding; J Lissner; K J Wolf
Journal:  J Magn Reson Imaging       Date:  1993 Jan-Feb       Impact factor: 4.813

View more
  21 in total

1.  Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.

Authors:  J Hwang; S H Kim; M W Lee; J Y Lee
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

Review 2.  Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid.

Authors:  Francesco Agnello; Marco Dioguardi Burgio; Dario Picone; Federica Vernuccio; Giuseppe Cabibbo; Lydia Giannitrapani; Adele Taibbi; Antonino Agrusa; Tommaso Vincenzo Bartolotta; Massimo Galia; Roberto Lagalla; Massimo Midiri; Giuseppe Brancatelli
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.

Authors:  Jean-Nicolas Vauthey; Elijah Dixon; Eddie K Abdalla; W Scott Helton; Timothy M Pawlik; Bachir Taouli; Antoine Brouquet; Reid B Adams
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

4.  The value of gadoxetic acid-enhanced MRI for differentiation between hepatic microabscesses and metastases in patients with periampullary cancer.

Authors:  Seo-Youn Choi; Young Kon Kim; Ji Hye Min; Dong Ik Cha; Woo Kyoung Jeong; Won Jae Lee
Journal:  Eur Radiol       Date:  2017-03-24       Impact factor: 5.315

5.  [Rational imaging of hepatocellular carcinoma. The challenge of multimodal diagnostic criteria].

Authors:  A Kircher; G Bongartz; E M Merkle; C J Zech
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

6.  The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging.

Authors:  Azusa Kitao; Osamu Matsui; Norihide Yoneda; Kazuto Kozaka; Rieko Shinmura; Wataru Koda; Satoshi Kobayashi; Toshifumi Gabata; Yoh Zen; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Eur Radiol       Date:  2011-05-29       Impact factor: 5.315

Review 7.  New paradigm for management of hepatocellular carcinoma by imaging.

Authors:  Ijin Joo; Byung Ihn Choi
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 8.  Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.

Authors:  Ahmed Ba-Ssalamah; Martin Uffmann; Sanjai Saini; Nina Bastati; Christian Herold; Wolfgang Schima
Journal:  Eur Radiol       Date:  2008-09-23       Impact factor: 5.315

9.  Small (<or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT.

Authors:  R Golfieri; E Marini; A Bazzocchi; F Fusco; F Trevisani; C Sama; G Mazzella; S Cavuto; F Piscaglia; L Bolondi
Journal:  Radiol Med       Date:  2009-08-20       Impact factor: 3.469

10.  SPIO-enhanced MRI findings of well-differentiated hepatocellular carcinomas: correlation with MDCT findings.

Authors:  Seong Hyun Kim; Won Jae Lee; Hyo K Lim; Cheol Keun Park
Journal:  Korean J Radiol       Date:  2009-03-03       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.